FY2026 EPS Estimates for Oculis Cut by Lifesci Capital

Oculis Holding AG (NASDAQ:OCS) – Research analysts at Lifesci Capital decreased their FY2026 EPS estimates for shares of Oculis in a research report issued on Thursday, May 7th. Lifesci Capital analyst P. Dolezal now expects that the company will post earnings per share of ($1.90) for the year, down from their previous estimate of ($1.89). The consensus estimate for Oculis’ current full-year earnings is ($2.17) per share.

Oculis (NASDAQ:OCS) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.54) by ($0.07). Oculis had a negative net margin of 8,173.41% and a negative return on equity of 62.12%. The business had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.25 million.

Several other equities analysts have also recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Oculis in a research report on Tuesday, April 21st. Wall Street Zen cut shares of Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Needham & Company LLC lifted their target price on shares of Oculis from $36.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. HC Wainwright reissued a “buy” rating and set a $44.00 target price on shares of Oculis in a research report on Monday, April 20th. Finally, Stifel Nicolaus lifted their target price on shares of Oculis from $40.00 to $50.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Oculis presently has an average rating of “Moderate Buy” and an average price target of $43.86.

Oculis Price Performance

Oculis stock opened at $32.65 on Tuesday. Oculis has a 52 week low of $16.00 and a 52 week high of $34.47. The company’s 50 day moving average price is $27.18 and its two-hundred day moving average price is $24.33. The company has a quick ratio of 5.96, a current ratio of 5.96 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1.89 billion, a P/E ratio of -14.38 and a beta of 0.38.

Institutional Investors Weigh In On Oculis

A number of hedge funds have recently modified their holdings of the stock. Bank of America Corp DE raised its holdings in shares of Oculis by 2.2% in the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after purchasing an additional 878 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of Oculis by 100.0% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after purchasing an additional 1,000 shares during the period. Aventura Private Wealth LLC bought a new stake in shares of Oculis in the 4th quarter worth approximately $80,000. Geode Capital Management LLC raised its holdings in shares of Oculis by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after purchasing an additional 6,384 shares during the period. Finally, Koshinski Asset Management Inc. bought a new stake in shares of Oculis in the 1st quarter worth approximately $238,000. Institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.